US audience sizing

Vyzulta & Lumigan patients

Estimated US patients currently treating with either brand

450,000 – 550,000

Vyzulta

latanoprostene bunod

75,000 – 110,000

est. total US patients · Growing — nearly 3× since 2020

YearPatientsClaimsSpend
202028,139101,073$37.6M
202257,544206,403$86.5M
202475,825292,207$128.3M

Medicare Part D beneficiaries

Lumigan

bimatoprost, branded

340,000 – 450,000

est. total US patients · Declining — losing share to generics

YearPatientsClaimsSpend
2020382,8511,718,576$633.5M
2022366,3331,606,849$701.3M
2024336,8701,407,999$647.2M

Medicare Part D beneficiaries

Source: CMS Medicare Part D Spending by Drug (data.cms.gov), through 2024. Totals beyond Medicare are estimates; commercial/cash detail requires IQVIA or Symphony claims data.